Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the differences between HIPEC and PIPAC in the treatment of patients with metastatic colorectal cancer.
The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.
Fox Chase Cancer Center hired Alexander R. Vartanov, MD, as an assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.
The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.
Bria-IMT plus an immune checkpoint inhibitor completely resolved a breast cancer metastasis and shrunk an eye-bulging orbital lesion in 1 patient.
Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.
Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.
Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
An NDA seeking the approval of camrelizumab plus rivoceranib for the frontline treatment of patients with unresectable HCC has been resubmitted to the FDA.
No significant improvement in OS was observed with Dato-DXd vs chemotherapy in pretreated HR-positive, HER2-low or -negative metastatic breast cancer.
